Oxyphytosterols are present in plasma of healthy human subjects

Andrè Grandgirard1*, Lucy Martine1, Luc Demaison1, Catherine Cordelet1, Corinne Joffre1, Olivier Berdeaux1 and Etienne Semon2

1Unité de Nutrition Lipidique, INRA, 17 rue Sully, BP 86510, 21065 DIJON cedex, France
2Laboratoire de Recherches sur les Arômes, INRA, Dijon, France

(Received 5 June 2003 – Revised 15 September 2003 – Accepted 16 September 2003)

The oxidised derivatives of phytosterols (oxyphytosterols) were identified in plasma samples from thirteen healthy human volunteers, using MS. All the samples contained noticeable quantities of (24R)-5β,6β-epoxy-24-ethylcholestan-3β-ol (β-epoxysitostanol) and (24R)-ethylcholestan-3β,5α,6β-triol (sitostanetriol) and also trace levels of (24R)-5α,6α-epoxy-24-ethylcholestan-3β-ol (α-epoxysitostanol), (24R)-methylcholestan-3β,5α,6β-triol (campestanetriol) and (24R)-ethylcholest-5-en-3β-ol-7-one (7-ketositosterol). The amounts of these oxyphytosterols in plasma varied from 4.8 to 57.2 ng/ml. There are two possibilities concerning the origin of these compounds. First, they could come from the small amounts of oxyphytosterols in food. Second, they could originate from the in vivo oxidation of phytosterols in plasma. Very few data actually exist concerning these compounds. Their identification in human samples suggests that further research is necessary in this field.

Oxyphytosterols: Phytosterols: Human plasma: Mass spectrometry

Plant sterols (phytosterols) display hypocholesterolaemic properties due to their effective inhibition of cholesterol absorption (Piironen et al. 2000). These compounds recently gained much interest; the esterification of phytosterols has allowed their incorporation in large quantities into margarines without changing their physical properties. For the last few years, numerous studies have been carried out showing the effectiveness of dietary phytosterols and of phytosterol-derived stanols in improving lipoprotein profiles in hypercholesterolaemic and normocholesterolaemic subjects (Piironen et al. 2000). This led to an increasing availability of phytosterol-enriched foods, as spreads or yoghurts. As a consequence, this will probably enhance the level of plant sterols in human circulation.

These plant sterols can be oxidised, as can cholesterol (Daly et al. 1983). The oxysterols, oxidised sterols obtained from cholesterol, have been extensively studied during the last 30 years; they exhibit many important biological properties including the modulation of cholesterol biosynthesis and metabolism (Guardiola et al. 1996; Janowski et al. 1996). These compounds are also suspected to be involved in atherosclerosis (Peng et al. 1991; Garcia-Cruste et al. 2002). Some of them are synthesised in vivo (Breuer & Bjorkhem, 1995), but they can also be formed in foods (Addis, 1986) and absorbed (Emanuel et al. 1991; Osada et al. 1994; Diczfalusy, 2002). Concerning the phytosterol oxides (oxyphytosterols), very few data are available. In some studies, small quantities were identified in foods (Lee et al. 1985; Nourooz-Zadeh & Appelqvist, 1992; Dutta, 1997; Dutta & Appelqvist, 1997; Dutta & Savage, 2002). In a recent experiment (Grandgirard et al. 1999), it was observed that a small quantity of these oxyphytosterols is absorbed by the intestine in rats. However, it was not known if these compounds were present in the tissues of healthy man. The oxides of plant sterols have only been described in two pathological situations. An old study mentioned that α- and β-epoxides of sitosterol were observed in the plasma of a patient with Waldenström’s macroglobulinaemia (Brooks et al. 1983). A very recent work (Plat et al. 2001) allowed the detection of large levels of oxyphytosterols (4-67 μg/ml) in the serum of phytosterolaemic patients. In this later study, no oxyphytosterols were identified in the serum of control subjects. The present study was conducted to determine if small amounts of such compounds could be identified in the plasma of healthy human volunteers.

Experimental procedures

Reagents

Pyridine was from Sigma (L’Isle d’Abeau, France). It was dehydrated and maintained on 4 Å molecular sieves. (25R)-cholest-5-en-3β,26-diol (27-hydroxycholesterol) was...

Abbreviations: Campestanetriol, (24R)-methylcholestan-3β,5α,6β-triol; α-epoxysitostanol, (24R)-5α,6α-epoxy-24-ethylcholestan-3β-ol; β-epoxysitostanol, (24R)-5β,6β-epoxy-24-ethylcholestan-3β-ol; 19-hydroxycholesterol, cholest-5-en-3β,19-diol; 27-hydroxycholesterol, (25R)-cholest-5-en-3β,26-diol; 7-ketositosterol, (24R)-ethylcholest-5-en-3β-ol-7-one; sitostanetriol, (24R)-ethylcholestan-3β,5α,6β-triol; TBME, tert-buty methyl ether; TMSOH, hydroxytrimethylsilyl fragment.

* Corresponding author: Dr Andrè Grandgirard, fax +33 3 80 69 32 32, email grandgi@dijon.inra.fr
provided by Steraloids (Wilton, NH, USA). The oxyphytosterols were synthesised and characterised in a previous study (Grandgirard et al. 1999). Cholest-5-en-3β,19-diol (19-hydroxycholesterol) and the other oxysterol standards were from Sigma (L’Isle d’Abeau, France). Butylated hydroxytoluene, tert-butyl methyl ether (TBME) and EDTA were obtained from Merck (Darmstadt, Germany). The silylation reagent bis-trimethylsilyl-trifluoroacetamide with 1 % trimethylchlorosilane was from Pierce (Rockford, IL, USA). The other solvents were obtained from SDS (Peypin, France) and were distilled before use.

**Experiment and oxysterols analysis**

Blood samples of 20 ml were collected from thirteen healthy human fasting volunteers (three women and ten men; aged 27 to 58 years; three of them were smokers) onto EDTA. The plasma was immediately obtained by centrifugation. The entire plasma obtained (more than 10 ml) was used for further analyses. The lipids were rapidly extracted using the method of Moilanen & Nikkari (1981) modified by adding 0.05 % butylated hydroxytoluene as antioxidant. After the addition of 19-hydroxycholesterol as the internal standard, the lipids were saponified for 1 d, in the dark, under N2, at room temperature, using 2M-ethanolic potassium hydroxide (10 ml). After adding 20 ml purified water, non-saponifiable matter was extracted twice by 20 ml dichloromethane. The two dichloromethane fractions were gathered and washed several times with water until neutral pH was reached. This fraction was then redissolved in 500 μl hexane–TBME (90:10, v/v) and purified by solid-phase extraction on a common method (GC quantification of the TMSE derivatives of the unsaponifiable fraction) (Lai et al., 1995). As recommended by Lai et al. (1995), a vacuum manifold (Supelco) was used to ensure a regular solvent flow rate of 0.6 ml/min through the cartridge. The oxysterols were then obtained with 5 ml aceton. After the evaporation of solvents, the samples were redissolved in 200 μl anhydrous pyridine and 200 μl bis-trimethylsilyl-trifluoracetamide containing 1 % added trimethylchlorosilane. The trimethylsilyl ether (TMSE) derivatives were obtained by heating for 30 min at 60°C. The reagents were evaporated under N2 and the residue dissolved in hexane for gas chromatographic analysis.

**Gas chromatography—mass spectrometry**

The TMSE derivatives were analysed by GC–MS using a 5890 Hewlett-Packard (Les Ulis, France) gas chromatograph coupled to a 5970 mass selective detector. The carrier gas was He. The injection was made in the splitless mode. A 30 m × 0.25 mm internal diameter HP-5 column (Hewlett-Packard) was used. The thickness of the film was 0.25 μm. After 1 min at 50°C, the oven temperature was raised at 20°C/min until 270°C, and then reached 290°C at 1°C/min. The oven temperature remained at 290°C during 35 min until the end of the analysis. The transfer line was operated at 290°C. The mass spectrometer was operated at an ionisation energy of 70 eV. Mass spectra were recorded between 50 and 700 atomic mass units. Quantitative analyses were performed by GC–MS in the selected ion monitoring mode, using the m/z 353 (19-hydroxycholesterol; internal standard), 431 ((24R)-ethylcholestan-3β,5α,6β-triol; sitostanetriol), 470 ((24R)-methylcholestan-3β,5α,6β-triol; campestanetriol), 500 ((24R)-ethylcholestan-5-en-3β-ol-7-one; 7-ketositosterol) and 502 ((24R)-3β,6β-epoxy-24-ethylcholestan-3β-ol (β-epoxysterostanol) and (24R)-5α,6α-epoxy-24-ethylcholestan-3β-ol (α-epoxysterostanol). Using these methods, the detection limits were comprised between 0.4 and 0.9 ng.

**Use of 2H-labelled cholesterol for monitoring sterol oxide formation during analysis**

A human plasma sample was analysed for phytosterols using a common method (GC quantification of the TMSE derivatives of the unsaponifiable fraction) (Giacometti, 2001). The value obtained for sitosterol (2.09 mg/l) was used for monitoring the eventual formation of artifact oxyphytosterols during analysis. So, 20-9 µg cholesterol-2,2,3,4,6-d6, (CDN Isotopes, Pointe Claire, Quebec, Canada) were added to 10 ml human plasma. The level of 2H labelling was 98 % and was checked by GC–MS before analysis. The analysis was made two times. The method used was identical to that described before for oxyphytosterols. In MS, the mass ions 462, 480, 552 and 478 were checked for hydroxycholesterols, epoxycholesterols, cholestanetriol and 7-ketocholesterol, respectively.

**Use of campesterol and sitosterol for evaluating sterol oxide formation during analysis**

A blend of phytosterols (ICN, Orsay, France) containing 51.3 % sitosterol, 28.5 % campesterol, 10 % stigmasterol, 65 % brassicasterol and 1.5 % Δ5-avenasterol, was submitted to four successive crystallisations in acetone. The obtained product was purified twice on silica cartridges, in order to get rid of the eventual oxyphytosterols. It contained 69-4 % campesterol, 28-1 % sitosterol, 1 % brassicasterol and 0-9 % stigmasterol. This product was used to make another checking of the absence of artifact oxyphytosterols formed during analysis. Portions of 74-4 μg each of this blend were added to three samples of human plasma (10 ml) and pair-wise compared with three samples of non-supplemented plasma. All the analyses of oxyphytosterols were carried out as described before.

**Results and discussion**

All plasma samples contained the same oxyphytosterols; they were identified using their retention times and by comparison of their mass spectra with those of the standards synthesised during a previous experiment (Grandgirard et al. 1999). Fig. 1 shows the full mass electronic impact spectra of β-epoxysterostanol and sitostanetriol, as well as the monitoring of some characteristic ions, corresponding to β-epoxysterostanol (502, 412), campestanetriol (560 and 470), α-epoxysterostanol.
(502 and 412) and sitostanetriol (574, 484) as TMSE derivatives. The α-epoxysitostanol and campestanetriol are minor compounds having close retention times with a large peak of 27-hydroxycholesterol (Fig. 2). The ions 546 (M+), 531 (M+-CH3), 456 (M+ - TMSOH), 441 (M+ - TMSOH-CH3), 417 (M+ - ring A), 380 (M+ - 2TMSOH-H2O) and 335 come from campestanetriol (di-TMSE derivative). As proved by Park & Addis (1989), the derivatisation of triols in these conditions furnished the di-TMSE derivative and the molecular ion is difficult to observe. It could be remarked that some ions may come from several compounds as 417 and 73.

A trace level of 7-ketositosterol (Fig. 3) was also detected (retention time 30.73 min). The ions 500 (M+), 485 (M+ - CH3), 483, 444, 410 (M+ - TMSOH), 395 (M+ - CH3-TMSOH), 161, 129 and 73 are characteristic of 7-ketositosterol. A contaminant compound is also present (ion 130). There is also a possibility of the presence of a small quantity of 7β-hydroxysterosterol, with the same retention time as cholest-5-en-3β,25-diol (25-hydroxycholesterol) and an unknown compound. However this hypothesis is based only on the m/z 484 and has to be ascertained using complementary studies. The quantitative data concerning these compounds (Table 1) indicates that...
their levels were not negligible even though they are of minor importance compared with the oxycholesterols detected in human plasma (Dzeletovic et al. 1995). However, the oxyphytosterols are rather different from the plasma oxycholesterols; they are essentially epoxides and compounds issued from epoxides such as triols. In contrast to oxycholesterols, they did not contain significant amounts of hydroxy- or keto- compounds. It is also important to note that the campesterol oxide in plasma and it was present at a low level. The phytosterol oxides issued from other phytosterols (stigmasterol, brassicasterol, Δ5-avenasterol, etc) were not detected.

It would probably have been very interesting to use 2H-labelled sitosterol for monitoring an eventual formation of artifacts, as already effected with cholesterol (Wasilchuk et al. 1992). However the only commercial compound is a blend of 2H-labelled phytosterols (sitosterol, campesterol, stigmasterol and probably some other minor sterols). The present authors think that the possibility of overlapping of compounds presenting the same ions in MS is very important. Then it was decided to use 2H-labelled cholesterol for checking the eventual formation of artifactual oxyphytosterols. There is no reason that cholesterol will be oxidised in a different manner compared with campesterol and sitosterol. The addition of 2H-labelled cholesterol equivalent to the amount of plasma sitosterol did not allow the observation of any 2H-labelled oxycholesterol. Another checking experiment was carried out by adding campesterol and sitosterol to three samples of human plasma in order to obtain a level double for sitosterol and almost double for campesterol. This did not allow the observation of an increase in oxyphytosterols. Moreover, in human plasma samples the campesterol levels are often higher than those of sitosterol (Kempen et al. 1991); in the present checking study, the level of campesterol in human plasma was 3-5 times higher than that of sitosterol. If the oxyphytosterols were artifacts, much more oxycampesterols compared with oxyzosterols would have been observed. This was not the case, and only a very small quantity of campestanetriol was observed. All these observations strengthen the opinion that these compounds are not artifacts.

The fact that these oxyphytosterols were not identified in recent studies on oxycholesterols in plasma is not very surprising. First the chromatograms of oxycholesterols always contained some unknown compounds. Then, selective ion monitoring was often used to quantify the oxycholesterols. This technique is very selective, but does not allow the identification of new compounds. Finally, in the present authors’ experience, some saponification or alkaline hydrolysis techniques can be deleterious for sterol epoxides and triols (A Grandgirard and J Demaison-Meloche, unpublished results). The oxyphytosterols were previously detected only in the plasma of patients with Waldenström macroglobulinaemia (Brooks et al. 1983) or phytosterolaemia (Plat et al. 2001). In this case, the level of oxyphytosterols were very important in plasma; 2330 ng α-epoxysitosterol/ml in phytosterolaemic patients compared with only 5.5 ng α-epoxysitosterol/ml and 57.2 ng β-epoxysitosterol/ml in healthy volunteers in the present study. In the same study, Plat et al. (2001) did not identify any oxyphytosterols in control serum. However, they used as the internal standard

![Fig. 3. Electronic impact mass spectrum of compound with a retention time of 33.7 min (not represented on Fig. 1) from a purified sterol oxides fraction coming from a plasma sample of a healthy human volunteer (as trimethylsilyl ether derivative).](https://www.cambridge.org/core/core/terms.https://doi.org/10.1079/BJN20031025)

### Table 1. Oxyphytosterol levels in plasma samples of thirteen healthy human volunteers (ng/ml plasma)

<table>
<thead>
<tr>
<th>Volunteer</th>
<th>β-Epoxyssitostanol</th>
<th>α-Epoxyssitostanol</th>
<th>Campestanetriol</th>
<th>Sitostanetriol</th>
<th>7-Ketositosterol</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>42.0</td>
<td>4.9</td>
<td>4.1</td>
<td>25.3</td>
<td>23.2</td>
</tr>
<tr>
<td>B</td>
<td>59.4</td>
<td>3.5</td>
<td>6.5</td>
<td>63.5</td>
<td>3.9</td>
</tr>
<tr>
<td>C</td>
<td>68.2</td>
<td>7.7</td>
<td>5.5</td>
<td>31.8</td>
<td>7.7</td>
</tr>
<tr>
<td>D</td>
<td>56.1</td>
<td>4.7</td>
<td>5.2</td>
<td>56.0</td>
<td>3.4</td>
</tr>
<tr>
<td>E</td>
<td>65.6</td>
<td>5.1</td>
<td>4.1</td>
<td>28.8</td>
<td>2.5</td>
</tr>
<tr>
<td>F</td>
<td>76.7</td>
<td>5.8</td>
<td>7.3</td>
<td>69.1</td>
<td>10.2</td>
</tr>
<tr>
<td>G</td>
<td>72.2</td>
<td>6.0</td>
<td>3.4</td>
<td>33.0</td>
<td>3.7</td>
</tr>
<tr>
<td>H</td>
<td>51.3</td>
<td>4.9</td>
<td>5.2</td>
<td>27.9</td>
<td>7.7</td>
</tr>
<tr>
<td>I</td>
<td>41.8</td>
<td>6.0</td>
<td>3.9</td>
<td>25.4</td>
<td>4.7</td>
</tr>
<tr>
<td>J</td>
<td>61.8</td>
<td>5.9</td>
<td>4.3</td>
<td>62.7</td>
<td>5.3</td>
</tr>
<tr>
<td>K</td>
<td>62.7</td>
<td>6.9</td>
<td>4.3</td>
<td>26.7</td>
<td>3.2</td>
</tr>
<tr>
<td>L</td>
<td>43.1</td>
<td>3.7</td>
<td>2.8</td>
<td>27.8</td>
<td>n.d.</td>
</tr>
<tr>
<td>M</td>
<td>42.5</td>
<td>6.2</td>
<td>5.7</td>
<td>31.3</td>
<td>3.7</td>
</tr>
<tr>
<td>Mean</td>
<td>57.2</td>
<td>5.5</td>
<td>4.8</td>
<td>39.1</td>
<td>6.1</td>
</tr>
<tr>
<td>so</td>
<td>12.1</td>
<td>1.2</td>
<td>1.3</td>
<td>16.7</td>
<td>5.7</td>
</tr>
</tbody>
</table>

n.d., not detected.
a blend of multi-2H-labelled oxyphytosterols (6·5 to 8·9 % d0; 3·9 to 4·2 % d1; 7·3 to 9·2 % d2; 20·3 to 21·2 % d3; 29·8 to 31·9 % d4; 22·4 % d5; 2·7 to 5·7 % d6; 1·8 to 1·9 % d7). The blend was obtained from a mixture of phytosterols (sitosterol, campesterol, stigmasterol and probably some other minor sterols). This did not allow a sensitive and precise quantification, due to the overlapping of compounds presenting the same ions in MS. They indeed described a limit of detection of 0·41 to 0·83 µg/ml compared with 0·4 to 0·9 ng for 10 ml plasma in the present study. This could explain the apparent discrepancies between the two studies.

The source of these plasma oxyphytosterols is actually difficult to establish. The diet origin is possible; these compounds are formed in food and can be absorbed in small quantities. In rats, Grandgirard et al. (1999) observed a lower absorption of 7-ketophytosterols compared with epoxy derivatives; the low levels of 7-ketositosanol in sitostanetriol was shown as less efficient than that of β-epoxysitostanol (Aringer & Eneroth, 1974). This could explain the low level of α-epoxysitostanol compared with β-epoxysitostanol in human plasma. However in the same study, Aringer & Eneroth (1974) showed that the β-epoxides were formed in three- to four-fold excess over the α-epoxides; this could be a sign that the observed oxyphytosterols are formed in vivo from the corresponding non-oxidised phytosterols. Further studies are necessary to conclude on this point. The fact that the oxyxycampesterols are observed only as traces compared with oxysitosanol could be explained by a higher metabolic rate.

In some cases, cholestanetriol is pointed out as one of the more cytotoxic oxysterols (Peng et al. 1979) and its involvement in atherogenesis has been considered (Jacobson et al. 1985; Matthias et al. 1987). It could be interesting to know if the phytosterol-derived triols observed in human plasma have the same biological properties. Finally, it would be interesting to investigate whether a larger consumption of phytosterols can lead to an increase of oxyphytosterols in human plasma. This point will be the matter of new experiments.

Acknowledgement

The authors thank Dr M. Lefort (Laboratoire Régional de Biologie Médicale, Dijon, France) for his help in blood collection from human volunteers.

References


